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Accepted 11 July 2017Background: Percutaneous coronary intervention (PCI) reduces mortality in most myocardial infarction (MI)
patients but the effect on elderly patients with comorbidities is unclear. Our aim was to analyse the effect of
PCI on in-hospital mortality of MI patients, by age, sex, ST elevation on presentation, diabetes mellitus (DM)
and chronic kidney disease (CKD).
Methods: Cohort study of 79,791MI patients admitted at European hospitals during 2000–2014. The effect of PCI
on in-hospital mortality was analysed by age group (18–74, ≥75 years), sex, presence of ST elevation, DM and
CKD, using propensity scorematching. The number needed to treat (NNT) to prevent a fatal eventwas calculated.
Sensitivity analyses were conducted.
Results: PCI was associated with lower in-hospital mortality in ST and non-ST elevation MI (STEMI and NSTEMI)
patients. The effect was stronger in men [Odds ratio (95% conﬁdence interval) 0.30 (0.25–0.35)] than in women
[0.46 (0.39–0.54)] aged ≥75 years, and in NSTEMI [0.22 (0.17–0.28)] than in STEMI patients [0.40 (0.31–0.5)]
aged b75 years. PCI reduced in-hospital mortality risk in patients with and without DM or CKD (54–72% and
52–73% reduction in DM and CKD patients, respectively). NNT was lower in patients with than without
CKD [≥75 years: STEMI = 6(5–8) vs 9(8–10); NSTEMI = 10(8–13) vs 16(14–20)]. Sensitivity analyses such as
exclusion of hospital stays b2 days yielded similar results.Keywords:
Percutaneous coronary intervention
Myocardial infarction
Diabetes mellitus
Chronic kidney disease
Elderlyliability and freedom from bias of the data presented and their discussed interpretation.
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84 I.R. Dégano et al. / International Journal of Cardiology 249 (2017) 83–89Conclusions: PCI decreased in-hospital mortality in MI patients regardless of age, sex, and presence of ST eleva-
tion, DM and CKD. This supports the recommendation for PCI in elderly patients with DM or CKD.
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Current guidelines recommend percutaneous coronary intervention
(PCI) for most patients with ST elevation acute myocardial infarction
(STEMI) or with non ST elevation acute coronary syndrome (NSTEACS)
[1–3]. In STEMI, PCI is advised in all patients in the ﬁrst 12 h after
symptom onset, the earlier the better [1,2]. In NSTEACS, the treatment
strategy is to perform PCI during the ﬁrst 72 h if patients have at least
one intermediate risk criterion such as diabetes mellitus (DM), chronic
kidney disease (CKD), or reduced left ventricular ejection fraction,
among others [3].
The recommendation stands for elderly patients (aged 75 years and
older), as it has been shown that STEMI and NSTEACS patients have
reasonable outcomes when treated invasively [4–7]. In elderly acute
coronary syndrome (ACS) patients, individual circumstances including
life expectancy, quality of life, and comorbidities should also be taken
into account [2,6,8–11]. While comorbidities are one of the decisional
factors that determine an invasive strategy in elderly ACS patients,
there is no speciﬁc advice concerning elderly patients with comorbidi-
ties in current guidelines.
Two of the most common comorbidities in elderly ACS patients
are DM and CKD, each one affecting 20–30% of this population [12].
Management of STEMI patients with DM should be the same as for
individuals without DM [2]. In NSTEACS patients with DM, an invasive
strategy is recommended over non-invasive management [3]. Advise-
ment on managing CKD is only available for NSTEACS patients, in
which coronary angiography and revascularization, if needed, are
recommended after assessment of beneﬁts, risks, and the severity of
renal dysfunction [3,13]. There are no studies comparing survival
outcomes after revascularization in elderly ACS patients with and
without DM and only one small study has analysed revascularization
and mortality in association with renal function in elderly NSTEACS
patients [14].
The goal of this study was to provide robust data on the effect of PCI
on in-hospital mortality risk in patients withmyocardial infarction (MI)
with andwithout ST elevation, by age group, sex, and presence of DMor
CKD.2. Methods
2.1. Data source
The EUROTRACS (EUROpean Treatment & Reduction of Acute Coronary Syndromes
cost analysis) database contains data on 94,474 ACS patients admitted in European
hospitals during 2000–2014. The EUROTRACS database includes 3 European registries of
ACS patients (EURHOBOP [15] – EURopean Hospital Benchmarking by Outcomes in ACS
Processes-, EuroHeart Survey I [16] and EuroHeart Survey II [17]), and 6 national/regional
registries (GreekHELIOS [18]–Hellenic InfarctionObservation Study-MI registry; regional
health information system from Lazio [19], Italy; Spanish MASCARA [20] – Manejo del
Síndrome Coronario Agudo. Registro Actualizado- ACS registry; MONICA/KORA [21] MI
registry from Augsburg, Germany; REGICOR [22] – REgistre GIroní del COR- MI registry
from Girona, Spain; and the Italian MCH-ESREFO [23] registry). Main characteristics
of the registries are described in Suppl. Table 1. The EUROTRACS Study was approved by
the Hospital del Mar review committee.2.2. Design and study population
This was a cohort study of patients from the EUROTRACS database designed as a
matched analysis by a propensity score (PS) for PCI use. Patients were followed during
their hospital stay for the occurrence of all-cause mortality. We included all EUROTRACS
component registries with information on diagnosis and on the required covariates, andselected patients aged ≥18 years with a diagnosis of MI. As shown in Suppl. Fig. 1 79,791
MI patients were included.
2.3. Study variables
The primary outcome of the study was in-hospital mortality and the exposure of
interest was use of PCI during hospitalization, independently of the type (primary, rescue,
elective, other) and the time since onset of symptoms. Other variables of interest included
age, sex, initial presence of ST elevation, DM, and CKD. Age was categorized in 2 groups:
18–74 and ≥75 years. Presence of DM was based on previous history, and CKD was
based on previous history and on the estimated glomerular ﬁltration rate (eGFR). The
eGFR was calculated with admission creatinine using the 4-component Modiﬁcation of
Diet in Renal Disease equation [24]. CKD was assumed if previous history or if the eGFR
was b60 mL/min/1.73 m2.
2.4. Potential confounders of PCI use
To select potential confounders of PCI use to construct the PS, we explored the associ-
ation of pre-PCI variables with PCI use and with the outcome (in-hospital mortality). We
selected all available pre-PCI variables associated with PCI use and in-hospital mortality
once variables with excessive missing values were excluded from statistical analysis.
Ten variables were selected: age, sex, hypertension, DM, CKD, previous history of MI,
admission Killip class, initial presence of ST elevation, year of treatment (categorized in
3 groups: 2000–2004, 2005–2009 and 2010–2014), and hospital characteristics such as
university hospital, on-site catheterization laboratory and coronary surgery.
2.5. Statistical analysis
Variables with N50% of missing values in the EUROTRACS database and/or 100%
missing in any of the component registries were excluded from the analysis. The remain-
ing variables had b4% of missing data in the EUROTRACS database. Missing data was
completedwith 20multiple imputations by chained equations [25]. Analyseswere carried
out in the 20 multiple imputed datasets and then estimates were combined.
Demographic and clinical data were summarized by themean and standard deviation
(SD) or by frequencies for continuous (normally distributed) or categorical variables,
respectively. Means and frequencies were compared between groups using ANOVA or
chi-squared tests, respectively.
Four separate analyses were undertaken to examine the in-hospital mortality risk
of patients who received PCI compared to those who did not: by age group and sex;
by age group and ST elevation; by age group, ST elevation, and DM; and by age group,
ST elevation, and CKD.
The PS was computed as the predicted values of PCI use from a logistic regression
model taking the selected potential confounders as the predictor variables. The variables
used to stratify risk (age, sex, ST elevation, DM, and CKD, depending on the analysis)
were not included in the PS used in the speciﬁc stratiﬁed analysis. Every patient receiving
PCI was matched with one patient who did not receive PCI, according to their PS values
within a caliper of 0.2 of the logit-transformed PS SD [26]. Balance of covariates was
assessed by computing the standardized differences between patients who did or did
not receive PCI [27].
In-hospital mortality and its 95% conﬁdence interval (CI) were calculated for each
group under analysis. The odds ratio (OR) of in-hospital mortality and its 95% CI for
patients receiving PCI compared to the rest were calculated using conditional logistic
regression. These models were adjusted for the variables not sufﬁciently balanced after
PS matching (standardized difference N 10%). In-hospital mortality estimates and ORs
between groups were compared using the chi-square test and z-scores, respectively,
and adjusted for multiple comparisons with the Bonferroni correction.
The number needed to treat (NNT) to prevent one in-hospital deathwas calculated as
the inverse of the absolute risk reduction as follows: 1/(MnonPCI−MPCI), where MnonPCI
andMPCI are the average in-hospitalmortality rates predicted by a non-conditional logistic
model as if all individuals received PCI and as if none of them received PCI, respectively.
Matched pairs were introduced in the non-conditional model as a random effects factor.
Several sensitivity analyses were carried out. First, patients who stayed b2 days at
the hospital were excluded. Second, stratiﬁcation was used instead of matching. OR of
in-hospital mortality for patients receiving PCI compared to the rest were obtained by
PS tertile, age group (18–59, 60–69, 70–79, and N79 years), and sex/ST elevation using
mixed effects logistic regression. PS models included the same variables as the PS of the
main analysis except for age.Models for in-hospitalmortality included PCI use, the speciﬁc
PS (logit-transformed), age, thrombolysis, coronary artery bypass grafting (CABG), and
maximum Killip class during hospitalization as ﬁxed effects, and country as a random
effect. Finally, analyses were undertaken using non-conditional instead of conditional
Table 1
Demographic and clinical characteristics of the study population by age group.
b75 years
(n = 51,747)
≥75 years
(n = 28,044)
p-Value
Age 60.4 ± 9.8 82.2 ± 5.2 b0.001
Sex: Female 22.9% 49.1% b0.001
Diabetes 17.8% 20.8% b0.001
Hypertension 34.9% 37.7% b0.001
Chronic kidney disease 7.4% 13.5% b0.001
Previous MI 15.3% 19.6% b0.001
Admission Killip class: III-IV 3.8% 7.1% b0.001
Type of MI b0.001
STEMI 52.2% 37.3%
NSTEMI 44.6% 56.0%
Non-classiﬁable 3.2% 6.7%
On-site catheterization laboratory 79.7% 70.1% b0.001
On-site cardiac surgery department 42.5% 30.0% b0.001
University hospital 36.1% 26.7% b0.001
Admission year b0.001
2000–2004 20.1% 12.3%
2005–2009 31.9% 27.0%
2010–2014 48.0% 60.7%
Thrombolysis 11.8% 4.3% b0.001
PCI 56.7% 31.4% b0.001
CABG 4.0% 1.3% b0.001
Maximum Killip class: III-IV 4.4% 7.5% b0.001
In-hospital mortality 4.4% 14.9% b0.001
All variables are presented as percentages except for age, which is presented asmean and
standard deviation. CABG, coronary artery bypass grafting; NSTEMI, non ST-elevation
myocardial infarction; MI, myocardial infarction; PCI, percutaneous coronary intervention;
STEMI, ST-elevation myocardial infarction.
85I.R. Dégano et al. / International Journal of Cardiology 249 (2017) 83–89logistic regression, and adjusting the in-hospital mortality models for moderators such as
thrombolysis, CABG, and maximum Killip class during hospitalization.
All analyses were performed with the R statistical software (version 3.2.3) [28].
3. Results
3.1. Baseline characteristics and matching
Demographic and clinical data by age group are presented in Table 1.
Patients aged ≥75 years had a higher prevalence of DM, hypertension,
CKD, previous MI, and cardiogenic shock or acute pulmonary edema
on admission, compared to younger patients. Older MI patients were
more frequently admittedwith non-ST elevationMI (NSTEMI). The pro-
portion of patients who received revascularization or were admitted atFig. 1. Effect of percutaneous coronary intervention on in-hospital mortality risk by age group
STEMI, ST elevation myocardial infarction. * indicates statistical signiﬁcance. Signiﬁcance was aa centrewith anon-site catheterization laboratorywas lower in patients
aged ≥75 years, compared to younger patients. Patient characteristics
by registry are described in Suppl. Table 2.
From the 79,791 patients who fulﬁlled the inclusion criteria
of the study, a median of 64% was matched by PS (interquartile
range, 53–70%), depending on the subgroup under analysis. Number
of individuals by group before and after matching is shown in
Suppl. Table 3.
3.2. In-hospital mortality
Crude in-hospital mortality was signiﬁcantly lower in men than in
women in patients regardless of age (Suppl. Table 4). STEMI patients
had higher in-hospital mortality than NSTEMI in both age groups.
STEMI patients with DM had higher in-hospital mortality than patients
without DM regardless of the age group, while NSTEMI patients with
DM had a signiﬁcantly higher in-hospital mortality only in patients
aged b75 years (Suppl. Table 4). Both STEMI and NSTEMI patients
with CKD had signiﬁcantly higher in-hospital mortality than patients
without CKD in both age groups.
3.3. Effect of PCI on in-hospital mortality risk
PCI use signiﬁcantly decreased in-hospital mortality risk in MI
patients regardless of age group, sex and ST characteristics (Fig. 1).
Men and women younger than 75 years beneﬁted similarly from PCI
use, while the risk reduction was signiﬁcantly larger in men aged
≥75 years compared to women of the same age (70% [65–75%] vs
54% [46–61%], p-value b0.001). The in-hospital mortality risk reduction
due to PCI usewas similar in STEMI andNSTEMI patients aged ≥75 years
butwas signiﬁcantly larger in younger patients withNSTEMI, compared
to STEMI (78% [72–83%] vs 60% [50–69%], p-value b0.001).
Fig. 2 shows the ORs of in-hospital mortality by presence of
DM and CKD and age group for STEMI and NSTEMI patients. The
use of PCI signiﬁcantly decreased in-hospital mortality risk across
all variables: STEMI and NSTEMI patients with and without DM or
CKD, in both age groups.
3.4. Number needed to treat
NNTs to prevent one in-hospital death by age group, sex, ST eleva-
tion, and presence of DM or CKD are shown in Fig. 3. NNTs were signif-
icantly lower in STEMI than in NSTEMI patients [b75 years: 24(21–29), sex, and ST elevation on presentation. NSTEMI, non ST elevation myocardial infarction;
djusted for multiple comparisons and assumed when b0.0025.
Fig. 2. Effect of percutaneous coronary intervention on in-hospital mortality risk by age group, ST elevation on presentation and presence of diabetes mellitus or chronic kidney disease.
CKD, chronic kidney disease; NSTEMI, non ST elevation myocardial infarction; STEMI, ST elevation myocardial infarction.
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women (Fig. 3A). As for patients with and without DM, NNTs were
lower in patients with DM in NSTEMI patients aged b75 years (21Fig. 3. Number needed to treat (NNT) to avoid one in-hospital death. NNT by age group, sex, a
diabetes mellitus (B); NNT by age group, ST elevation on presentation and chronic kidney
diabetes mellitus; CKD, chronic kidney disease; NSTEMI, non ST elevation myocardial infarctio(19–25) vs 40 (35–46)) (Fig. 3B). NNTs were also signiﬁcantly lower
in patients with CKD than in those without CKD in STEMI and NSTEMI
patients younger than 75 years [STEMI: 10(8–14) vs 27(22−33);nd ST elevation on presentation (A); NNT by age group, ST elevation on presentation and
disease (C) in patients with myocardial infarction from the EUROTRACS database. DM,
n; STEMI, ST elevation myocardial infarction. * indicates statistical signiﬁcance.
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9(8–10); NSTEMI: 10(8–13) vs 16(14–20)] (Fig. 3C).
3.5. Sensitivity analyses
Exclusion of hospital stays shorter than 2 days resulted in similar OR
for in-hospital mortality in all subgroups (Suppl. Figs. 2 and 3). Stratiﬁ-
cation analyses showed that PCI use decreased in-hospitalmortality risk
in MI patients in the 4 age groups analysed regardless of sex and initial
presence of ST elevation. Only in 2 groups (women aged 18–59 years in
the 1st PS tertile and NSTEMI patients aged 18–59 years in the 3rd PS
tertile) PCI did not signiﬁcantly decrease in-hospital mortality risk
(Suppl. Figs. 4 and 5). Non-conditional regression analysis and models
withmoderators showed similar results compared to themain analyses
(Suppl. Tables 5 and 6).
4. Discussion
The analysis of 79,791 contemporary European MI patients showed
that PCI use was associated with lower in-hospital mortality. This
association was observed in both men and women and in patients
with STEMI and NSTEMI, becoming signiﬁcantly larger in men than
in women in the group aged ≥75 years, while the effect was larger in
NSTEMI than in STEMI patients aged b75 years. PCI use was associated
with lower in-hospital mortality in patients with and without DM
and in those with and without CKD, independently of age group and ST
elevation. In addition, the NNT for patients with CKD compared to those
without CKD was lower in all age groups in STEMI and NSTEMI patients,
and inNSTEMI patients younger than 75 years theNNTwas lower for DM
than for non-DM patients.
In accordancewith our results, a number of studies in the last decade
have shown that an invasive strategy or PCI use is associatedwith lower
in-hospital to 1-year mortality in both younger and elderly patients
with ACS [5–11,29–32]. A subgroup analysis of elderly patients with
STEMI in 11 randomized trials showed a reduction in 30-day mortality
in patients older than 70 years receiving primary PCI (PPCI) compared
to thrombolysis [29]. In a more recent trial, a trend towards a reduction
in 30-day mortality was found for PPCI compared to thrombolysis in
patients older than 75 years [7]. Similarly, in the MINAP registry, an
invasive versus conservative strategy reduced the risk of 1-yearmortal-
ity in both younger and elderly patients [29]. Our results point in the
same direction, showing lower in-hospital mortality of STEMI patients
aged b75 and ≥75 years who received PCI versus no PCI.
As for NSTEMI patients, an invasive strategy was associated with
lower in-hospital and 1-year mortality in patients ≥75 years from a
German ACS registry [8]. In this registry, there was no in-hospital mor-
tality beneﬁt in women receiving an invasive strategy [33]. Our analysis
showed a beneﬁt in both men and women, although in the oldest
patients (aged ≥75 years) the effect was signiﬁcantly larger in men.
The larger effect in older men could be due to the more atypical symp-
toms in older women and the reported delay in their post-MI hospital
admission [34,35]. Investigators from the GRACE and MINAP registries
and a recent clinical trial have also found that an invasive strategy re-
duced 6-month and 1-year mortality, as well as a composite outcome
of MI, need for urgent revascularization, stroke and death, in elderly
NSTEACS patients [10,31,36]. Our results also showed lower in-hospital
mortality in NSTEMI patients who received PCI, independently of age.
In contrast to theGRACE andMINAP results [10,31], we did notﬁnd a
smaller effect in the oldest age group (≥75 years). This difference may
be due to new guideline-recommended medications (antiplatelet
agents, statins, beta-blockers and angiotensin converting enzyme
inhibitors/angiotensin receptor blockers [ACEIs/ARBs]) [30] being avail-
able to the patients included in our study, which in turn would yield
fewer complications and better outcomes. In addition, the introduction
of PCI trans-radial arterial access, particularly in ST elevation ACSpatients, would reduce access site complications, which are a major
cause of mortality after PCI in elderly patients [37].
It is intriguing that PCI had a larger effect on reducing in-hospital
mortality in patients younger than 75 years with NSTEMI, compared
to patients with STEMI, in our study. Several factors likely inﬂuenced
this result. On the one hand, STEMI is associated with a higher risk of
in-hospital mortality than NSTEMI [38], and unsuccessful PCI has a
larger impact on mortality in STEMI than in NSTEMI [39]. On the other
hand, it is possible that patients with STEMI in our sample were in
worse condition than NSTEMI patients, as the proportion of patients
presenting with cardiogenic shock or pulmonary oedema on admission
was higher in STEMI than in NSTEMI (5.21 vs 3.77%, p-value b 0.001).
Our results showing a protective effect of PCI on in-hospital mortal-
ity in individuals with and without DM are in line with current STEMI
and NSTEACS guidelines [2,3], which recommend similar management
of patients with and without DM. Our data also provide new evidence
for the consideration of PCI in elderly patients with DM. Our results
are in accordance with a meta-analysis of randomized trials, which
showed that an invasive strategy reduced cardiovascular events similar-
ly in diabetic and non-diabetic patients with NSTEACS at 12-month
follow-up and that the reduction of recurrent nonfatal MI was greater
in patients with DM [40].
In the analysis of patients with and without CKD, a protective effect
of PCI on in-hospital mortality was observed in both groups. In a
Swedish nationwide register, better 1-year survival was also observed
in NSTEMI patients younger than 80 years undergoing invasive therapy,
particularly in individuals with mild-to-moderate renal insufﬁciency
[13]. A small prospective study also showed that coronary revasculari-
zation decreases the risk of 1-year mortality in elderly patients with
NSTEACS independently of creatinine clearance [14]. Our results
reinforce the ﬁndings in the elderly population with NSTEMI and
provide new evidence for the consideration of PCI in STEMI patients
regardless of age, despite a lack of relevant recommendations in current
guidelines.
4.1. Study limitations
The present analysis is an observational study, which could affect
the reliability of results due to selection and survival bias, among others.
Efforts to reinforce reliability included use of the EUROTRACS database,
which has a large sample size and includes patients fromdifferent coun-
tries and hospitals, and the application of robust statistical methods
such as PS matching and a number of sensitivity analyses. In particular,
survival bias was assessed by a sensitivity analysis excluding hospital
stays b2 days. This analysis yielded results similar to the main analysis.
A limitation in assessing outcomes in elderly ACS patients after PCI is the
lack of information on bleeding. Although we could not examine bleed-
ing events in our study, a recent clinical trial comparing an invasive and
a conservative strategy in NSTEMI patients aged ≥80 years found no
differences in bleeding complications [36]. Outcomes after PCI are also
affected by time to PCI and by type of PCI, and they are interrelated,
particularly in STEMI. In STEMI and in high-risk NSTEACS patients, the
shorter the time to PPCI and invasive strategy the better the short-
and long-term outcomes [41–47]. In addition, in STEMI patients, PPCI
yields better outcomes than other revascularization and PCI types,
although in speciﬁc settings primary and rescue PCI may be comparable
[1,48]. Unfortunately, we did not have information on time to PCI and
type of PCI, and it is possible that the inclusion of these two variables
could have affected our results. Another potential limitation was the
lack of frailty measures, as individuals with frailty havemore cardiovas-
cular disease and vice versa. However, frailty is highly correlated with
variables included in the PS, such as age, renal impairment and Killip
class [49], so we would not expect a signiﬁcant change in the results
if frailty measures were included. Finally, medications (such as anti-
platelet agents, statins, beta-blockers and ACEIs/ARBs) and comorbidi-
ties other than CKD, DM, hypertension, and previous MI, for example
88 I.R. Dégano et al. / International Journal of Cardiology 249 (2017) 83–89the Charlson comorbidity index, were not included in the analysis
because these data were not available in the EUROTRACS database. A
study analysing a large ACS registry found no signiﬁcant changes in
the effect of reperfusion or an invasive strategy when including the
mentioned medications or a few comorbidities [31]. However, older
adults can be prescribed with many other drugs which may cause
high-risk events such as bleeding. In addition, elderly comorbidities
include cognitive impairment, dementia, and disability which inﬂuence
clinical decision making and may affect the results of this study [50].
4.2. Conclusion
Patients withMIwho received a PCI during hospital admission had a
lower risk of in-hospital mortality regardless of sex, age, presence of ST
elevation, and DMor CKD. These results add up to the existing literature
for patients younger than 75 years and provide robust evidence for the
indication of PCI in elderly MI patients with DM and CKD presenting
with or without ST elevation.
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